Bioventus Inc. Class A Common Stock (MM) News - BIOV

Bioventus Inc. 4721 Emperor Boulevard, Suite 100 Durham, North Carolina 27703 (919) 474-6700 August&nb...

Table of Contents As filed with the Securities and Exchange Commission on July 27...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

As filed with the Securities and Exchange Commission on July 25, 2016 Registration No. 333-212329 ...

GAITHERSBURG, Md., June 26 /PRNewswire-FirstCall/ -- BioVeris Corporation (NASDAQ:BIOV) announced today that on June 25, 2007, at a Special...

GAITHERSBURG, Md., June 14 /PRNewswire-FirstCall/ -- BioVeris Corporation (NASDAQ:BIOV), today released the following comment on the...

GAITHERSBURG, Md., June 7 /PRNewswire-FirstCall/ -- BioVeris Corporation (NASDAQ:BIOV) reported today its financial results for the quarter and...

GAITHERSBURG, Md., May 15 /PRNewswire-FirstCall/ -- BioVeris Corporation ("BioVeris") (NASDAQ:BIOV) announced today that its Board of Directors...

GAITHERSBURG, Md., April 4 /PRNewswire-FirstCall/ -- BioVeris Corporation (NASDAQ:BIOV) announced today that the Company has reached a...

Cytokine Biomarkers and Antibody Panels Introduced For Sale GAITHERSBURG, Md., Feb. 13 /PRNewswire-FirstCall/ -- BioVeris Corporation...

GAITHERSBURG, Md., Feb. 6 /PRNewswire-FirstCall/ -- BioVeris Corporation (NASDAQ:BIOV) reported today the financial results for its fiscal third...

New License Adds Neisseria meningitidis group Y and Haemophilus influenzae type b to Bioveris's Vaccine Candidate Portfolio GAITHERSBURG, Md...

BioVeris Appoints Auditor to Examine Roche's Books and Records for 2004 and 2005 GAITHERSBURG, Md., Jan. 8 /PRNewswire-FirstCall/ -- BioVeris...

Combination Vaccine Candidates Will Use Neisseria meningitidis Group C Components GAITHERSBURG, Md., Dec. 26 /PRNewswire-FirstCall/ -- BioVeris...

GAITHERSBURG, Md., Nov. 6 /PRNewswire-FirstCall/ -- BioVeris Corporation (NASDAQ:BIOV) reported today the financial results for its fiscal...